Congress caps drug costs for ACA patients at $2,000 annually
H.R. 6171 — ACA Copay CAP Act of 2025 · Filed by Jake Auchincloss (D-MA) · Introduced Nov 20, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps the annual out-of-pocket costs that patients must pay for prescription drugs under ACA health plans at $2,000 for individual coverage (starting in 2027), with family coverage capped at $4,000. The cap increases annually with medical inflation. Once a patient hits the cap, their health plan covers 100% of remaining drug costs for the rest of that year.
Why we flagged it
The bill's core mechanism is a straightforward consumer protection: capping annual out-of-pocket drug spending under ACA plans. It is not a tax measure, subsidy, or deregulation—it is a direct limit on what patients must pay.
What the text implies
- Pharmaceutical manufacturers may face indirect pressure to negotiate lower prices with insurers, since insurers will absorb costs above the patient cap and may push back on drug pricing.
- The cap applies only to ACA marketplace plans and employer plans subject to ACA rules; uninsured patients and those in non-ACA plans receive no benefit.
The full analysis lists 4 implications of this text.
Who stands to gain
patients with chronic conditions requiring expensive drugs; low-income and middle-income households with high drug costs